Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 38, Issue 1-2, 2000, Pages 91-101

  Vose, Julie M ^a   Colcher, David ^a   Gobar, Lisa ^a   Bierman, Philip J ^a   Augustine, Samuel ^a   Tempero, Margaret ^a   Leichner, Peter ^a   Lynch, James C ^a   Goldenberg, David ^a   Armitage, James O ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

Author keywords

131Iodine labelled; Anti CD22; Monoclonal antibody; Recurrent non Hodgkin's lymphoma

Indexed keywords

ANTIBODY; CD22 ANTIGEN; EPRATUZUMAB; IODINE 131; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; BLOOD AUTOTRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOPENIA; DOSE RESPONSE; DRUG EFFICACY; DRUG TOXICITY; FEMALE; HUMAN; HYPOTHYROIDISM; MALE; MOUSE; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE;

EID: 18244429971     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009060322     Document Type: Article

References (24)

1. Velasquez WS, McLaughlin P, Tucker S, et al: (1994) ESHAP - An Effective Chemotherapy Regimen in Refractory and relapsing lymphoma: A 4-year follow-up study. J Clin Oncol 12: 1169-1176,.
2. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ: IMVP-16: (1982) An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 60: 693-697.
3. Gallagher CJ, Gregory WM, Jones AE, et al: (1986) Follicular lymphoma prognostic factors for response and survival, J Clin Oncol 4: 1470-1474.
4. Paryani SB, Hoppe RT, Cox RS, et al: (1983) Analysis of non-Hodgkin's lymphomas with nodular and favourable histologies, stages I and II. Cancer 52: 2300-2305.
5. Rohatiner AZS, Johnson PWM, Price CGA, et al: (1994) Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 12: 1177-1184.
6. Bierman PJ, Vose JM, Anderson JR, et al: (1997) High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 15: 445-450.
7. Hokland P, Ritz J, Schlosman SF, Nadler LM: (1985) Orderly expression of B-cell antigens during the in vitro differentiation of nonmalignant human pre-B cells. J Immunol 135: 1746-1751, 1985.
8. Stashenko P, Nadler LM, Hardy R, et al: (1980) Characterization of a human B-lymphocyte specific antigen. J Immunol 125: 1678-1685.
9. Pawlak-Byczkowska EJ, Hansen HJ, Dion AS, et al: (1989) Two new monoclonal antibodies, EP B-1 and EPB-2, reactive with human lymphoma. Cancer Res 49: 4568-4577.
10. Goldenberg DM, Horowitz JA, Sharkey RM, et al: Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131 labeled LL2 monoclonal antibody. J Clin Oncol 9: 548-564, 1991.
11. Vose JM, Anderson JR, Kessinger A, et al: High-dose chemotherapy and autologous hematopoietic stem cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 11: 1846-1850, 1993.
12. Hunter WM, Greenwood FC: Preparations of iodine-131 labelled human growth hormone of high specific activity. Nature: 194: 495-496, 1962.
13. th International Radiopharmaceutical Dosimetry Symposium. Pp. 535-544. Oak Ridge, TN: Oak Ridge National Laboratory, 1985.
14. Loevinger R. and Berman M. A revised scheme for calculating the absorbed dose from biologically distributed radionuclide. In: Medical Internal Radiation Dose, Pamphlet 1, revised New York: Society of Nuclear Medicine, Inc. 1976.
15. Davis TA, Maloney DG, Liles TM, et al: Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood 92: 1184-1190, 1998.
16. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 16: 2825-2833, 1998.
17. 131I] Anti-B1 (Anti-CD20) antibody. N Engl J Med 329: 459-465, 1993.
18. Vose JM, Saleh M, Lister A, et al: Iodine-131 anti-B1 antibody for non-Hodgkin's lymphoma: overall clinical trail experience. Proc ASCO 17: 38a, 1998.
19. 131-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas. Lancet 346: 336-340, 1995.
20. Knox SJ, Goris ML, Strisler K, et al: Yttrium-90-labeled Anti-CD20 Monoclonal Antibody therapy of recurrent B-cell lymphoma. Clinical Cancer Res 2: 457-470, 1996.
21. White CA, Halpern SE, Parker BA, et al: Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 Anti-idiotype monoclonal antibodies. Blood 87: 3640-3649, 1996.
22. Shih LB, Lu H HZ, Xuan H and Goldenberg DM, Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2. Int J Cancer 56: 538-545, 1994.
23. Duncan JR and Welch MJ: Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. J Nucl Med 34: 1728-1738, 1993.
24. Behr TM, Sharkey RM, Juweid M, et al: Residualizing (indium, yttrium) versus released (iodine) isotopes in radioimmunodetection and therapy with internalizing antibodies (Abstract). J Nucl Med 36: 20, 1995.